Long-term results of extensive aortoiliac occlusive disease (EAIOD) treated by endovascular therapy and risk factors for loss of primary patency.
10.1097/CM9.0000000000001229
- Author:
Xiao-Lang JIANG
1
,
2
;
Yun SHI
;
Bin CHEN
;
Jun-Hao JIANG
;
Tao MA
;
Chang-Po LIN
;
Da-Qiao GUO
;
Xin XU
;
Zhi-Hui DONG
;
Wei-Guo FU
Author Information
1. Institute of Vascular Surgery, Department of Vascular Surgery, Zhongshan Hospital, Fudan University
2. Center for Vascular Surgery and Wound Care, Jinshan Hospital, Fudan University, Shanghai 201508, China.
- Publication Type:Journal Article
- MeSH:
Arterial Occlusive Diseases/surgery*;
Endovascular Procedures/methods*;
Female;
Humans;
Iliac Artery/surgery*;
Kaplan-Meier Estimate;
Male;
Middle Aged;
Retrospective Studies;
Risk Factors;
Stents;
Survival Rate;
Treatment Outcome;
Vascular Patency
- From:
Chinese Medical Journal
2020;134(8):913-919
- CountryChina
- Language:English
-
Abstract:
BACKGROUND:Although endovascular therapy has been widely used for focal aortoiliac occlusive disease (AIOD), its performance for extensive AIOD (EAIOD) is not fully evaluated. We aimed to demonstrate the long-term results of EAIOD treated by endovascular therapy and to identify the potential risk factors for the loss of primary patency.
METHODS:Between January 2008 and June 2018, patients with a clinical diagnosis of the 2007 TransAtlantic Inter-Society Consensus II (TASC II) C and D AIOD lesions who underwent endovascular treatment in our institution were enrolled. Demographic, diagnosis, procedure characteristics, and follow-up information were reviewed. Univariate analysis was used to identify the correlation between the variables and the primary patency. A multivariate logistic regression model was used to identify the independent risk factors associated with primary patency. Five- and 10-year primary and secondary patency, as well as survival rates, were calculated by Kaplan-Meier analysis.
RESULTS:A total of 148 patients underwent endovascular treatment in our center. Of these, 39.2% were classified as having TASC II C lesions and 60.8% as having TASC II D lesions. The technical success rate was 88.5%. The mean follow-up time was 79.2 ± 29.2 months. Primary and secondary patency was 82.1% and 89.4% at 5 years, and 74.8% and 83.1% at 10 years, respectively. The 5-year survival rate was 84.2%. Compared with patients without loss of primary patency, patients with this condition showed significant differences in age, TASC II classification, infrainguinal lesions, critical limb ischemia (CLI), and smoking. Multivariate logistic regression analysis showed age <61 years (adjusted odds ratio [aOR]: 6.47; 95% CI: 1.47-28.36; P = 0.01), CLI (aOR: 7.81; 95% CI: 1.92-31.89; P = 0.04), and smoking (aOR: 10.15; 95% CI: 2.79-36.90; P < 0.01) were independent risk factors for the loss of primary patency.
CONCLUSION:Endovascular therapy was an effective treatment for EAIOD with encouraging patency and survival rate. Age <61 years, CLI, and smoking were independent risk factors for the loss of primary patency.
